#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	.	174	174	.	+	.	"ID=ID_0;Name=;nt_name=c.G-92T;gene=orf1ab;mutation_type=;Reference_seq=G;Variant_seq=T;ao=6544;dp=6777;ro=223;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	241	241	.	+	.	"ID=ID_0;Name=;nt_name=c.C-25T;gene=orf1ab;mutation_type=;Reference_seq=C;Variant_seq=T;ao=6829;dp=6849;ro=17;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	1059	1059	.	+	.	"ID=ID_1;Name=p.T265I;nt_name=c.C794T;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6778;dp=6862;ro=81;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	2692	2692	.	+	.	"ID=ID_2;Name=p.T809T;nt_name=c.A2427T;gene=orf1ab;mutation_type=SILENT;Reference_seq=A;Variant_seq=T;ao=4824;dp=6862;ro=2032;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	3037	3037	.	+	.	"ID=ID_3;Name=p.F924F;nt_name=c.C2772T;gene=orf1ab;mutation_type=SILENT;Reference_seq=C;Variant_seq=T;ao=6835;dp=6862;ro=27;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	5230	5230	.	+	.	"ID=ID_4;Name=p.K1655N;nt_name=c.G4965T;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6600;dp=6862;ro=251;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	10323	10323	.	+	.	"ID=ID_5;Name=p.K3353R;nt_name=c.A10058G;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6754;dp=6862;ro=102;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	11287	11287	.	+	.	"ID=ID_6;Name=p.S3675_F3677del;nt_name=c.11023_11031delTCTGGTTTT;gene=orf1ab;mutation_type=;Reference_seq=GTCTGGTTTT;Variant_seq=G;ao=6402;dp=6862;ro=6755;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	11288	11288	.	+	.	"ID=ID_7;Name=p.S3675T;nt_name=c.T11023A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=269;dp=449;ro=145;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11289	11289	.	+	.	"ID=ID_8;Name=p.S3675Y;nt_name=c.C11024A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=N;ao=268;dp=448;ro=180;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11290	11290	.	+	.	"ID=ID_9;Name=p.S3675S;nt_name=c.T11025A;gene=orf1ab;mutation_type=SILENT;Reference_seq=T;Variant_seq=N;ao=261;dp=448;ro=187;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11291	11291	.	+	.	"ID=ID_10;Name=p.G3676S;nt_name=c.G11026A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=N;ao=264;dp=451;ro=132;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11292	11292	.	+	.	"ID=ID_11;Name=p.G3676D;nt_name=c.G11027A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=N;ao=262;dp=452;ro=190;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11293	11293	.	+	.	"ID=ID_12;Name=p.G3676G;nt_name=c.T11028A;gene=orf1ab;mutation_type=SILENT;Reference_seq=T;Variant_seq=N;ao=261;dp=452;ro=191;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11294	11294	.	+	.	"ID=ID_13;Name=p.F3677I;nt_name=c.T11029A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=264;dp=455;ro=191;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11295	11295	.	+	.	"ID=ID_14;Name=p.F3677Y;nt_name=c.T11030A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=262;dp=455;ro=193;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	11296	11296	.	+	.	"ID=ID_15;Name=p.F3677L;nt_name=c.T11031A;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=266;dp=456;ro=114;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	14408	14408	.	+	.	"ID=ID_16;Name=p.P4715L;nt_name=c.C14144T;gene=orf1ab;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6130;dp=6862;ro=8;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	21614	21614	.	+	.	"ID=ID_17;Name=p.L18F;nt_name=c.C52T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=2796;dp=6862;ro=4058;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1101/2021.01.14.426475;citation=""McCallum et al. (2021) "";comb_mutation=;function_description=""Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"";clade_defining=False;"
MN908947.3	.	.	21614	21614	.	+	.	"ID=ID_17;Name=p.L18F;nt_name=c.C52T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=2796;dp=6862;ro=4058;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03398-2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17."";clade_defining=False;"
MN908947.3	.	.	21614	21614	.	+	.	"ID=ID_17;Name=p.L18F;nt_name=c.C52T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=2796;dp=6862;ro=4058;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness."";clade_defining=False;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_18;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_19;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_20;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03398-2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_20;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_19;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_19;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_18;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_20;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""CD8 plus T cell response"";source=https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1;citation=""Redd et al. (2021) "";comb_mutation=;function_description=""One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern."";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_20;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type) "";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_18;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	21801	21801	.	+	.	"ID=ID_18;Name=p.D80A;nt_name=c.A239C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=6748;dp=6862;ro=106;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_18;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_21;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""homoplasy"";source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=""Borges et al. (2021) "";comb_mutation=;function_description=""In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. "";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_19;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_21;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_19;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_19;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_18;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_21;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_18;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	22206	22206	.	+	.	"ID=ID_18;Name=p.D215G;nt_name=c.A644G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6406;dp=6857;ro=436;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	22280	22280	.	+	.	"ID=ID_22;Name=p.L241_A243del;nt_name=c.719_727delCTTTACTTG;gene=S;mutation_type=;Reference_seq=ACTTTACTTG;Variant_seq=A;ao=6187;dp=6862;ro=6851;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	22281	22281	.	+	.	"ID=ID_23;Name=p.T240N;nt_name=c.C719A;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=N;ao=165;dp=627;ro=462;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22282	22282	.	+	.	"ID=ID_24;Name=p.T240T;nt_name=c.T720A;gene=S;mutation_type=SILENT;Reference_seq=T;Variant_seq=N;ao=271;dp=624;ro=353;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22283	22283	.	+	.	"ID=ID_25;Name=p.L241I;nt_name=c.T721A;gene=S;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=278;dp=624;ro=346;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22284	22284	.	+	.	"ID=ID_26;Name=p.L241X;nt_name=c.T722A;gene=S;mutation_type=NONSENSE;Reference_seq=T;Variant_seq=N;ao=318;dp=660;ro=342;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22285	22285	.	+	.	"ID=ID_27;Name=p.L241F;nt_name=c.A723C;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=N;ao=323;dp=660;ro=337;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22286	22286	.	+	.	"ID=ID_28;Name=p.L242I;nt_name=c.C724A;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=N;ao=326;dp=660;ro=334;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22287	22287	.	+	.	"ID=ID_29;Name=p.L242H;nt_name=c.T725A;gene=S;mutation_type=MISSENSE;Reference_seq=T;Variant_seq=N;ao=354;dp=649;ro=262;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22288	22288	.	+	.	"ID=ID_30;Name=p.L242L;nt_name=c.T726A;gene=S;mutation_type=SILENT;Reference_seq=T;Variant_seq=N;ao=357;dp=649;ro=284;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22289	22289	.	+	.	"ID=ID_31;Name=p.A243T;nt_name=c.G727A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=N;ao=354;dp=655;ro=267;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_18;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_19;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=""Sun et al. (2021) "";comb_mutation=;function_description="">20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=""Sun et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=""Wibmer et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03398-2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation=;function_description=""The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=""Laffeber et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=""Ramanathan et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.nature.com/articles/s41586-021-03412-7;citation=""Collier et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation=;function_description=""Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_35;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_36;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_37;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=""Teyssou et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=""Roquebert et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation=;function_description=""COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_38;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='E484K';function_description=""Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_39;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='N501Y';function_description=""COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_19;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'E484K';function_description=""~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation=;function_description=""In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1101/2021.01.18.427166;citation=""Wibmer et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=""Pearson et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=""Roquebert et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_19;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1056/NEJMoa2102214;citation=""Madhi et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'E484K';function_description=""In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_35;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_36;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_37;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_34;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'N501Y', 'D614G';function_description=""This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=""Bates et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_18;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_33;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=""Wu et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300."";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=""Starr et al. (2021) "";comb_mutation=;function_description=""Escape mutation against monoclonal antibody LY-CoV016"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""gene expression increase"";source=https://doi.org/10.1016/j.cell.2020.08.012;citation=""Starr et al. (2020) "";comb_mutation=;function_description=""Experimentally, Spike gene expression increased 0.1 fold"";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_32;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_18;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	22813	22813	.	+	.	"ID=ID_18;Name=p.K417N;nt_name=c.G1251T;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6500;dp=6862;ro=166;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""T cell evasion"";source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=""Reynolds et al. (2021) "";comb_mutation=;function_description=""Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_18;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_19;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=""Sun et al. (2021) "";comb_mutation=;function_description=""Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=""Sun et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03412-7;citation=""Collier et al. (2021) "";comb_mutation=;function_description=""Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=""Li et al. (2021) "";comb_mutation=;function_description=""Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=""Wibmer et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='N501Y';function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=""Gaebler et al. (2021) "";comb_mutation=;function_description=""Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=""Liu et al. (2020) "";comb_mutation=;function_description=""Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w;citation=""Chen et al. (2021) "";comb_mutation=;function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03398-2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://science.sciencemag.org/content/371/6531/823;citation=""Rappazzo et al. (2021) "";comb_mutation=;function_description=""Massive reduction in binding efficiency vs wild type for mAb LY-CoV555."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_42;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation='N501Y';function_description=""In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=""Laffeber et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=""Ramanathan et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.nature.com/articles/s41586-021-03412-7;citation=""Collier et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation=;function_description=""Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=""Zahradnik et al. (2021) "";comb_mutation=;function_description=""Among the first selected variants in an in vitro evolution experiment for ACE2 binding."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://doi.org/10.1016/j.cell.2020.08.012;citation=""Starr et al. (2020) "";comb_mutation=;function_description=""Experimentally, ACE2 binding affinity increased 0.06 fold"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_42;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_42;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_43;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_42;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_37;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'D614G';function_description=""Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=""Ferriera et al (2021) "";comb_mutation=;function_description=""This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=""Teyssou et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=""Roquebert et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation=;function_description=""Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_38;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='K417N';function_description=""Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='N501Y';function_description=""Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_43;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=""Tada et al. (2021) "";comb_mutation='D614G';function_description=""Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_19;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'K417N';function_description=""~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=""Tang et al. (2021) "";comb_mutation=;function_description=""As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation=;function_description=""Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=""Zhou et al. (2021) "";comb_mutation=;function_description=""Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='N501Y';function_description=""In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=""Liu et al. (2021) "";comb_mutation=;function_description=""Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41586-021-03398-2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1101/2021.01.18.427166;citation=""Wibmer et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=""Andreano et al. (2020) "";comb_mutation=;function_description=""This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=""Pearson et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=""Roquebert et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_43;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=""Tada et al. (2021) "";comb_mutation='D614G';function_description=""Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_19;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1084/jem.20202756;citation=""Solfrosi et al. (2021) "";comb_mutation=;function_description=""Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=""Ikegame et al. (2021) "";comb_mutation=;function_description=""E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1056/NEJMoa2102214;citation=""Madhi et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1016/S2666-5247(21;citation=""Jangra et al. (2021) "";comb_mutation=;function_description=""Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'K417N';function_description=""In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_43;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_42;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y', 'D614G';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_37;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'D614G';function_description=""This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_34;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'N501Y', 'D614G';function_description=""This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=""Ferreira et al. (2021) "";comb_mutation=;function_description=""Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=""Bates et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_18;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_33;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=""Wu et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.nature.com/articles/s41591-021-01294-w;citation=""Chen et al. (2021) "";comb_mutation='N501Y';function_description=""The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)]"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_41;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.nature.com/articles/s41591-021-01270-4;citation=""Xie et al. (2021) "";comb_mutation='N501Y';function_description=""In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=http://dx.doi.org/10.1126/science.abd0831;citation=""Baum et al. (2020) "";comb_mutation=;function_description=""Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=""Weisblum et al. (2020) "";comb_mutation=;function_description=""Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub;citation=""Barnes et al. (2020) "";comb_mutation=;function_description=""The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110)."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://doi.org/10.1016/j.chom.2020.11.007;citation=""Greaney et al. (2020) "";comb_mutation=;function_description=""Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=""Starr et al. (2021) "";comb_mutation=;function_description=""Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)"";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro."";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_40;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_18;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	23012	23012	.	+	.	"ID=ID_18;Name=p.E484K;nt_name=c.G1450A;gene=S;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=A;ao=6507;dp=6862;ro=331;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""immunosuppression variant emergence"";source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=""Choi et al. (2020) "";comb_mutation=;function_description=""Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""T cell evasion"";source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=""Reynolds et al. (2021) "";comb_mutation=;function_description=""Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).  Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_18;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""homoplasy"";source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=""Flores-Alanis et al. (2021) "";comb_mutation=;function_description=""Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_19;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=""Sun et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1101/2021.04.26.441517;citation=""Klegerman et al. (2021) "";comb_mutation=;function_description=""Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41586-021-03412-7;citation=""Collier et al. (2021) "";comb_mutation=;function_description=""Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=""Wibmer et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='E484K';function_description=""Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=""Haynes et al. (2021) "";comb_mutation=;function_description=""Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation=;function_description=""Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=""Shen et al. (2021) "";comb_mutation=;function_description=""Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=""Rees-Spear et al. (2021) "";comb_mutation=;function_description=""Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='D614G';function_description=""Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation=;function_description=""The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation='E484K';function_description=""In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=""Barton et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=""Motozono et al. (2021) "";comb_mutation=;function_description=""~4-fold increase in binding affinity vs wild type."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=""Santos and Passos (2021) "";comb_mutation=;function_description=""In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=""Laffeber et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=""Ramanathan et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.nature.com/articles/s41586-021-03412-7;citation=""Collier et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://doi.org/10.1016/j.cell.2020.08.012;citation=""Starr et al. (2020) "";comb_mutation=;function_description=""Experimentally, ACE2 binding affinity increased 0.24 fold"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=""Zahradnik et al. (2021) "";comb_mutation=;function_description=""Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=""Liu et al. (2021) "";comb_mutation=;function_description=""Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=""Tian et al. (2021) "";comb_mutation=;function_description=""Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=""Zhu et al. (2021) "";comb_mutation=;function_description=""N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=""Ramanathan et al. (2021) "";comb_mutation=;function_description=""Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""ACE2 receptor binding affinity"";source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=""Gamez et al. (2021) "";comb_mutation=;function_description=""The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='D614G';function_description=""~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='D614G';function_description=""More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_36;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'D614G';function_description=""~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'K417N', 'D614G';function_description=""~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=""Motozono et al. (2021) "";comb_mutation=;function_description=""Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=""Teyssou et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=""Roquebert et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=""Liu et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation=;function_description=""COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='E484K';function_description=""Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_39;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""pharmaceutical effectiveness"";source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=""Engelhart et al. (2021) "";comb_mutation='K417N';function_description=""COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_19;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation=;function_description=""0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=""Tang et al. (2021) "";comb_mutation=;function_description=""As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=""Shen et al. (2021) "";comb_mutation=;function_description=""Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=""Rathnasinghe et al. (2021) "";comb_mutation=;function_description=""In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=""Vogel et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.nature.com/articles/s41591-021-01294-w ;citation=""Chen et al. (2021) "";comb_mutation='E484K';function_description=""In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1101/2021.01.18.427166;citation=""Wibmer et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=""Pearson et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=""Roquebert et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_19;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=""Edara et al. (2021) "";comb_mutation=;function_description=""1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1056/NEJMoa2102214;citation=""Madhi et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_45;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='D614G';function_description=""This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_36;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'D614G';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'D614G';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_34;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'E484K', 'D614G';function_description=""This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=""Bates et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=""Bates et al. (2021) "";comb_mutation=;function_description=""Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=""Rathnasinghe et al. (2021) "";comb_mutation=;function_description=""Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=""Jacobson et al. (2021) "";comb_mutation=;function_description=""The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_18;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_33;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=""Wu et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.nature.com/articles/s41591-021-01294-w;citation=""Chen et al. (2021) "";comb_mutation='E484K';function_description=""The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)]"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_41;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.nature.com/articles/s41591-021-01270-4;citation=""Xie et al. (2021) "";comb_mutation='E484K';function_description=""In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""monoclonal antibody serial passage escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=""Wang et al. (2021) "";comb_mutation=;function_description=""In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613."";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""environmental condition stability"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour"";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_44;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_18;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	23063	23063	.	+	.	"ID=ID_18;Name=p.N501Y;nt_name=c.A1501T;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=T;ao=6733;dp=6862;ro=117;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_19;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation=;function_description=""Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y';function_description=""Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_42;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""syncytium formation"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation=;function_description=""~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y';function_description=""~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_42;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]"";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation=;function_description=""No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='N501Y';function_description=""More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_42;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.3390%2Fv13040633;citation=""Kim et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y';function_description=""9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K';function_description=""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_35;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N';function_description=""~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_36;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_42;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_37;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'K417N';function_description=""Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'K417N', 'N501Y';function_description=""~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y';function_description=""9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=""Barrett et al. (2021) "";comb_mutation=;function_description=""Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)"";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.nature.com/articles/s41467-020-19808-4;citation=""Zhang et l. (2020) "";comb_mutation=;function_description=""We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.nature.com/articles/s41467-021-21118-2;citation=""Ozono et al. (2020) "";comb_mutation=;function_description=""Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. "";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://doi.org/10.7554/elife.65365;citation=""Daniloski et al. (2021) "";comb_mutation=;function_description=""The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""viral load"";source=https://www.nature.com/articles/s41586-020-2895-3;citation=""Plante et al. (2020) "";comb_mutation=;function_description=""Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=""Tada et al. (2021) "";comb_mutation='E484K';function_description=""Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]"";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_19;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=""Hu et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=""Pearson et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. "";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""transmissibility"";source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=""Roquebert et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=""Tada et al. (2021) "";comb_mutation='E484K';function_description=""Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_19;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1056/NEJMoa2102214;citation=""Madhi et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='N501Y';function_description=""This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K';function_description=""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_35;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N';function_description=""This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_36;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'N501Y';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_42;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='E484K', 'N501Y';function_description=""This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_37;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'E484K';function_description=""This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation='K417N', 'E484K', 'N501Y';function_description=""This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype)."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=""Kuzmina et al. (2021) "";comb_mutation=;function_description=""Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. "";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1016/j.cell.2021.03.013;citation=""Garcia-Beltran et al. (2021) "";comb_mutation=;function_description=""Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.nature.com/articles/s41467-020-19808-4;citation=""Zhang et al. (2020) "";comb_mutation=;function_description=""Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=""Yurkovetskiy et al. (2020) "";comb_mutation=;function_description=""CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=""Weissman et al. (2020) "";comb_mutation=;function_description=""Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."";clade_defining=True;"
MN908947.3	.	.	23403	23403	.	+	.	"ID=ID_46;Name=p.D614G;nt_name=c.A1841G;gene=S;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=G;ao=6842;dp=6862;ro=20;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_18;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""symptom prevalence"";source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=""Munster et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=""Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_19;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""antibody epitope effects"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=""Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_47;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""trafficking"";source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=""Tada et al. (2021) "";comb_mutation=;function_description=""Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_19;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""convalescent plasma escape"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=""Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_19;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://doi.org/10.1126/science.abg9175;citation=""Stamatatos et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=""In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_18;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""vaccine neutralization efficacy"";source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=""Alenquer et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y';function_description=""Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres."";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_47;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""virion structure"";source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=""Spratt et al. (2021) "";comb_mutation=;function_description=""Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) "";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_18;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=""Yinda et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=""Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  "";clade_defining=True;"
MN908947.3	.	.	23664	23664	.	+	.	"ID=ID_18;Name=p.A701V;nt_name=c.C2102T;gene=S;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6781;dp=6862;ro=79;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category=""reinfection"";source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=""Staub et al. (2021) "";comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=""4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection."";clade_defining=True;"
MN908947.3	.	.	25563	25563	.	+	.	"ID=ID_48;Name=p.Q57H;nt_name=c.G171T;gene=ORF3a;mutation_type=MISSENSE;Reference_seq=G;Variant_seq=T;ao=6719;dp=6862;ro=124;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	25904	25904	.	+	.	"ID=ID_49;Name=p.S171L;nt_name=c.C512T;gene=ORF3a;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6620;dp=6862;ro=182;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	26456	26456	.	+	.	"ID=ID_50;Name=p.P71L;nt_name=c.C212T;gene=E;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6678;dp=6862;ro=176;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	28253	28253	.	+	.	"ID=ID_51;Name=p.F120F;nt_name=c.C360T;gene=ORF8;mutation_type=SILENT;Reference_seq=C;Variant_seq=T;ao=6584;dp=6846;ro=245;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	28254	28254	.	+	.	"ID=ID_52;Name=p.I121L;nt_name=c.A361C;gene=ORF8;mutation_type=MISSENSE;Reference_seq=A;Variant_seq=C;ao=2265;dp=6843;ro=4561;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
MN908947.3	.	.	28887	28887	.	+	.	"ID=ID_53;Name=p.T205I;nt_name=c.C614T;gene=N;mutation_type=MISSENSE;Reference_seq=C;Variant_seq=T;ao=6648;dp=6862;ro=209;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=True;"
MN908947.3	.	.	29868	29868	.	+	.	"ID=ID_0;Name=;nt_name=c.G*4484A;gene=S;mutation_type=;Reference_seq=G;Variant_seq=N;ao=343;dp=1141;ro=798;viral_lineage=B.1.351;who_label=Beta;status=VOC;function_category="""";source=;citation="""";comb_mutation=;function_description="""";clade_defining=False;"
